Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers

2.50
Hdl Handle:
http://hdl.handle.net/2336/12477
Title:
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers
Authors:
Pukkala, Eero; Andersen, Aage; Berglund, Göran; Gislefoss, Randi; Gudnason, Vilmundur; Hallmans, Göran; Jellum, Egil; Jousilahti, Pekka; Knekt, Paul; Koskela, Pentti; Kyyrönen, P Pentti; Lenner, Per; Luostarinen, Tapio; Löve, Arthur; Ogmundsdóttir, Helga; Stattin, Pär; Tenkanen, Leena; Tryggvadottir, Laufey; Virtamo, Jarmo; Wadell, Göran; Widell, Anders; Lehtinen, Matti; Dillner, Joakim
Citation:
Acta Oncol 2007, 46(3):286-307
Issue Date:
23-Apr-2007
Abstract:
The Nordic countries have a long tradition of large-scale biobanking and comprehensive, population-based health data registries linkable on unique personal identifiers, enabling follow-up studies spanning many decades. Joint Nordic biobank-based studies provide unique opportunities for longitudinal molecular epidemiological research. The purpose of the present paper is to describe the possibilities for such joint studies, by describing some of the major Nordic biobank cohorts with a standardised calculation of the cancer incidence in these cohorts. Altogether two million donors have since 1966 donated more than four million biological samples, stored at -20 degrees C to -135 degrees C, to 17 biobank cohorts in Finland, Iceland, Norway and Sweden. As a result of joint database handling principles, the accuracy of personal identifiers and completeness of follow-up for vital status in all participating biobanks was improved. Thereafter, the cancer incidence was determined using follow-up through the national cancer registries. Biobanks based on random samples of population typically showed slightly lower cancer incidence rates than the general population, presumably due to better participation rates among health-conscious subjects. On the other hand, biobanks including samples for viral screening or clinical testing showed 1.5 to 2.1 fold increased incidence of cancer. This excess was very high immediately after sampling, but for some cancer sites remained elevated for years after clinical sampling. So far, more than 100 000 malignant neoplasms have occurred after sample donation, and the annual increase of the cancer cases in these cohorts is about 10 000. The estimates on the population-representativity of the biobanks will assist in interpretation of generalizability of results of future studies based on these samples, and the systematic tabulations of numbers of cancer cases will serve in study power estimations. The present paper summarizes optimal study designs of biobank-based studies of cancer.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.informaworld.com/smpp/content?content=10.1080/02841860701203545

Full metadata record

DC FieldValue Language
dc.contributor.authorPukkala, Eero-
dc.contributor.authorAndersen, Aage-
dc.contributor.authorBerglund, Göran-
dc.contributor.authorGislefoss, Randi-
dc.contributor.authorGudnason, Vilmundur-
dc.contributor.authorHallmans, Göran-
dc.contributor.authorJellum, Egil-
dc.contributor.authorJousilahti, Pekka-
dc.contributor.authorKnekt, Paul-
dc.contributor.authorKoskela, Pentti-
dc.contributor.authorKyyrönen, P Pentti-
dc.contributor.authorLenner, Per-
dc.contributor.authorLuostarinen, Tapio-
dc.contributor.authorLöve, Arthur-
dc.contributor.authorOgmundsdóttir, Helga-
dc.contributor.authorStattin, Pär-
dc.contributor.authorTenkanen, Leena-
dc.contributor.authorTryggvadottir, Laufey-
dc.contributor.authorVirtamo, Jarmo-
dc.contributor.authorWadell, Göran-
dc.contributor.authorWidell, Anders-
dc.contributor.authorLehtinen, Matti-
dc.contributor.authorDillner, Joakim-
dc.date.accessioned2007-07-03T10:53:17Z-
dc.date.available2007-07-03T10:53:17Z-
dc.date.issued2007-04-23-
dc.date.submitted2007-07-03-
dc.identifier.citationActa Oncol 2007, 46(3):286-307en
dc.identifier.issn0284-186X-
dc.identifier.pmid17450464-
dc.identifier.doi10.1080/02841860701203545-
dc.identifier.otherVIR12-
dc.identifier.urihttp://hdl.handle.net/2336/12477-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe Nordic countries have a long tradition of large-scale biobanking and comprehensive, population-based health data registries linkable on unique personal identifiers, enabling follow-up studies spanning many decades. Joint Nordic biobank-based studies provide unique opportunities for longitudinal molecular epidemiological research. The purpose of the present paper is to describe the possibilities for such joint studies, by describing some of the major Nordic biobank cohorts with a standardised calculation of the cancer incidence in these cohorts. Altogether two million donors have since 1966 donated more than four million biological samples, stored at -20 degrees C to -135 degrees C, to 17 biobank cohorts in Finland, Iceland, Norway and Sweden. As a result of joint database handling principles, the accuracy of personal identifiers and completeness of follow-up for vital status in all participating biobanks was improved. Thereafter, the cancer incidence was determined using follow-up through the national cancer registries. Biobanks based on random samples of population typically showed slightly lower cancer incidence rates than the general population, presumably due to better participation rates among health-conscious subjects. On the other hand, biobanks including samples for viral screening or clinical testing showed 1.5 to 2.1 fold increased incidence of cancer. This excess was very high immediately after sampling, but for some cancer sites remained elevated for years after clinical sampling. So far, more than 100 000 malignant neoplasms have occurred after sample donation, and the annual increase of the cancer cases in these cohorts is about 10 000. The estimates on the population-representativity of the biobanks will assist in interpretation of generalizability of results of future studies based on these samples, and the systematic tabulations of numbers of cancer cases will serve in study power estimations. The present paper summarizes optimal study designs of biobank-based studies of cancer.en
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttp://www.informaworld.com/smpp/content?content=10.1080/02841860701203545en
dc.subject.meshBiological Specimen Banksen
dc.subject.meshNeoplasmsen
dc.subject.meshTissue Donorsen
dc.titleNordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancersen
dc.typeArticleen
dc.identifier.journalActa oncologica (Stockholm, Sweden)en
dc.format.digYES-

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.